Production (Stage)
BioAtla, Inc.
BCAB
$0.3896
$0.00832.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 11.00M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 11.00M | -- | -- |
| Cost of Revenue | 12.36M | 11.65M | 16.40M | 16.20M | 18.85M |
| Gross Profit | -12.36M | -11.65M | -5.40M | -16.20M | -18.85M |
| SG&A Expenses | 5.26M | 4.59M | 5.88M | 5.77M | 5.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.61M | 16.24M | 22.27M | 21.97M | 24.46M |
| Operating Income | -17.61M | -16.24M | -11.27M | -21.97M | -24.46M |
| Income Before Tax | -15.33M | -14.88M | -10.59M | -21.07M | -23.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.33M | -14.88M | -10.59M | -21.07M | -23.23M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.33M | -14.88M | -10.59M | -21.07M | -23.23M |
| EBIT | -17.61M | -16.24M | -11.27M | -21.97M | -24.46M |
| EBITDA | -17.43M | -16.02M | -11.04M | -21.74M | -24.22M |
| EPS Basic | -0.26 | -0.30 | -0.22 | -0.44 | -0.48 |
| Normalized Basic EPS | -0.16 | -0.19 | -0.14 | -0.27 | -0.30 |
| EPS Diluted | -0.26 | -0.30 | -0.22 | -0.44 | -0.48 |
| Normalized Diluted EPS | -0.16 | -0.19 | -0.14 | -0.27 | -0.30 |
| Average Basic Shares Outstanding | 58.25M | 49.65M | 48.34M | 48.21M | 48.09M |
| Average Diluted Shares Outstanding | 58.25M | 49.65M | 48.34M | 48.21M | 48.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |